Mission Bio, Inc., a South San Francisco, CA-based developer of a high throughput single-cell genomics system, secured a seed funding from angel investment group Life Science Angels (LSA).
The amount of the deal was not disclosed.
The company intends to use the funds to commercialize its system.
Led by Charlie Silver, chief executive officer, Mission Bio is developing a microfluidic, droplet-based platform to enable advances in diseases like cancer, where elucidating heterogeneity in cell populations is essential.
The company, which spun out of the University of California, San Francisco (UCSF) three years ago, secured U.S. National Institutes of Health (NIH) and U.S. National Science Foundation (NSF) grants and won the QB3@953 Amgen Golden Ticket Award and CYTO Innovation Award in 2016.
Earlier funding came from Tech Coast Angels and Keiretsu Forum, as well as other seed-stage investment funds.